Bone Marrow Transplant News and Research

RSS

Pleiotrophin protein may be long-sought growth factor for blood stem cells

Duke Medicine researchers studying the interaction of blood stem cells and the niche where they reside have identified a protein that may be a long-sought growth factor for blood stem cells.

24 Oct 2012

Merck, AiCuris enter licensing agreement for novel HCMV candidates

Merck, known as MSD outside the United States and Canada, and AiCuris today announced that they have entered into an exclusive worldwide licensing agreement for AiCuris' novel portfolio of investigational medicines targeting Human Cytomegalovirus (HCMV), including letermovir (AIC246), an oral, late-stage antiviral candidate being investigated for the treatment and prevention of HCMV infection in transplant recipients.

15 Oct 2012

Novel method can determine how ready acute myeloid leukemia cells are to die

Researchers at Dana-Farber Cancer Institute have developed a novel method for determining how ready acute myeloid leukemia (AML) cells are to die, a discovery that may help cancer specialists to choose treatments option more effectively for their patients who have AML.

12 Oct 2012

Haploidentical bone marrow transplants for sickle cell disease: an interview with Dr. Javier Bolaños Meade

Bone marrow transplant (also called stem cell transplant) is a medical intervention that allows a physician to deliver very high doses of chemotherapy (if needed) but more importantly, deliver a new immune system to the patient to fight a disease (such as cancer).

3 Oct 2012

Novel therapy shows promise in treating multiple myeloma following stem cell transplants

A novel therapy in the early stages of development at Virginia Commonwealth University Massey Cancer Center shows promise in providing lasting protection against the progression of multiple myeloma following a stem cell transplant by making the cancer cells easier targets for the immune system.

2 Oct 2012

Bone marrow transplants hold promise for sickle cell patients

Research shows that even partially matched bone marrow transplants are able to eliminate sickle cell disease in some patients with sickle cell anemia.

24 Sep 2012

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms and the need for a lifetime of pain medications and blood transfusions.

24 Sep 2012

Natural killer cells may influence lung cancer susceptibility

Why do many heavy smokers evade lung cancer while others who have never lit up die of the disease? The question has vexed scientists for decades.

24 Sep 2012

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially-matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms, and the need for a lifetime of pain medications and blood transfusions. The researchers say the use of such marrow could potentially help make bone marrow transplants accessible to a majority of sickle cell patients who need them.

21 Sep 2012

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

21 Sep 2012

New model reveals how immune system functions under conditions of neutropenia

Cancer chemotherapy can be a life-saver, but it is fraught with severe side effects, among them an increased risk of infection. Until now, the major criterion for assessing this risk has been the blood cell count: if the number of white blood cells falls below a critical threshold, the risk of infection is thought to be high.

12 Sep 2012

Study sheds new light on why most bone marrow transplant patients suffer acute GVHD

A team of scientists led by a bone marrow transplant researcher at Fred Hutchinson Cancer Research Center has shed new light on why most bone marrow transplant patients who receive tissue-matched cells from unrelated donors still suffer acute graft-versus-host disease (GVHD).

6 Sep 2012

Missing link between bone marrow stem cells and human immune system

UCLA researchers have discovered a type of cell that is the "missing link" between bone marrow stem cells and all the cells of the human immune system, a finding that will lead to a greater understanding of how a healthy immune system is produced and how disease can lead to poor immune function.

3 Sep 2012

Arteriocyte receives NIH grant for use of NANEX platform in bone marrow transplant

Arteriocyte, a leading clinical stage biotechnology company developing cellular based therapies to treat human diseases, announced today the successful award of another grant by the National Institute of Health for the use of the NANEX platform in Hematopoietic Reconstitution Using Ex Vivo Expanded Umbilical Cord Blood CD34+ Stem Cells.

22 Aug 2012

Mayo Clinic receives approval for construction of new building on Phoenix campus

Mayo Clinic has been granted approval for construction of a 217,200 square-foot building on its Phoenix campus, a major expansion that will create a single-site, integrated Cancer Center. Mayo Clinic Cancer Center is the only National Cancer Institute-designated comprehensive cancer center with a multi-site, national presence, which allows us to serve a broad and diverse group of patients.

21 Aug 2012

Longer looks: Waking up to the need for sleep

Among the more than 11,000 dearly departed inhabitants of Southeast Portland's Multnomah Park Cemetery, friends Eric Cordingley and David Anderson have their favorites: a reputed French madam, a young Norwegian institutionalized for being gay, and Louis Napoleon Lepley -- or, as they call him, "Louis the cannibal." Intriguing as their individual stories may be, together they help tell a bigger, darker tale

10 Aug 2012

New research center to expedite study of gene transfer approach

In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced today an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.

6 Aug 2012

Bone Marrow Transplant News and Research

Pleiotrophin protein may be long-sought growth factor for blood stem cells

Merck, AiCuris enter licensing agreement for novel HCMV candidates

Novel method can determine how ready acute myeloid leukemia cells are to die

Haploidentical bone marrow transplants for sickle cell disease: an interview with Dr. Javier Bolaños Meade

Novel therapy shows promise in treating multiple myeloma following stem cell transplants

Bone marrow transplants hold promise for sickle cell patients

Even partially matched bone marrow transplants can eliminate sickle cell disease in some patients

Natural killer cells may influence lung cancer susceptibility

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

Partially-matched bone marrow transplants can eliminate sickle cell disease in some patients

New model reveals how immune system functions under conditions of neutropenia

Study sheds new light on why most bone marrow transplant patients suffer acute GVHD

Missing link between bone marrow stem cells and human immune system

Arteriocyte receives NIH grant for use of NANEX platform in bone marrow transplant

Mayo Clinic receives approval for construction of new building on Phoenix campus

Longer looks: Waking up to the need for sleep

New research center to expedite study of gene transfer approach

Novartis, Penn partner to study and commercialize novel cellular immunotherapies for cancer

Australia's top medical researchers for 2012 announced

Research presented at AIDS 2012 conference renews hope of cure for AIDS

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News